Smith+Nephew reported a 3.1% rise in first-quarter underlying revenue, supported by strong sports medicine and wound management performance. The company kept its annual outlook unchanged and announced a $500 million share buyback, signaling confidence in cash generation and capital returns.
Smith+Nephew reported a 3.1% rise in first-quarter underlying revenue, supported by strong sports medicine and wound management performance. The company kept its annual outlook unchanged and announced a $500 million share buyback, signaling confidence in cash generation and capital returns.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.45
